Breast Cancer as Isolated Axillary Lymphadenopathy

10.5580/2b48 ◽  
2012 ◽  
Vol 11 (2) ◽  
Keyword(s):  
Breast Cancer ◽  
Axillary Lymphadenopathy

scholarly journals Atypical axillary lymphadenopathy mimicking an occult breast carcinoma in a patient diagnosed with sarcoidosis: case report

Mastology ◽  
2020 ◽  
Vol 30 (Suppl 1) ◽  
Author(s):  
Paula Clarke ◽  
Carolina Nazareth Valadares ◽  
Douglas de Miranda Pires ◽  
Nayara Carvalho de Sá
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Breast Carcinoma ◽  
Lymph Nodes ◽  
Axillary Lymph Nodes ◽  
Breast Lesions ◽  
Axillary Lymph ◽  
Axillary Lymphadenopathy ◽  
Granulomatous Lymphadenitis ◽  
Occult Breast Carcinoma

Introduction: Occult breast carcinoma is a rare presentation of breast cancer, with histological evidence of axillary lymph node involvement and clinical and radiological absence of malignant breast lesions. Its survival is similar to that of the usual presentation. The treatment consists of modified radical mastectomy or axillary drainage with breast irradiation, resulting in similar survival, associated with systemic therapy according to the staging. Neoadjuvant therapy should be considered in N2-3 axillary cases. Differential diagnoses of axillary lymphadenopathies include: non-granulomatous causes (reactive, lymphoma, metastatic carcinoma) and granulomatous causes (infectious – toxoplasmosis, tuberculosis, sarcoidosis, atypical mycobacteria). Objectives: To report the case of a patient who needed a differential diagnosis among the various causes of axillary lymphadenopathy. Methods: This is a literature review conducted in the PubMed database, using the keywords "granulomatous lymphadenitis", "breast sarcoidosis", "occult breast cancer". Inclusion and exclusion criteria were applied. Case report: V.F.S., female, 51 years old, was referred to an evaluation of axillary lymphadenopathy in May 2019. She was followed by the department of pulmonology due to mediastinal sarcoidosis since 2017. Physical examination indicated breasts without changes. Axillary lymph nodes had increased volume and were mobile and fibroelastic. Mammography revealed only axillary lymph nodes with bilaterally increased density, and the ultrasound showed the presence of atypical bilateral lymph nodes. Neither presented breast lesions. Axillary lymph node core biopsy was compatible with granulomatous lymphadenitis. This result corroborates the diagnosis of sarcoidosis affecting peripheral lymph nodes. The patient was referred back to the department of pulmonology, with no specific treatment since she is oligosymptomatic. Discussion: Despite the context of benign granulomatous disease, malignancy overlying the condition of sarcoidosis must be ruled out. The biopsy provided a safe and definitive diagnosis, excluding the possibility of occult breast carcinoma. The patient will continue to undergo breast cancer screening as indicated for her age and usual risk. Conclusion: In the presentation of axillary lymphadenopathy, the mastologist must know the various diagnoses to be considered. The most feared include lymphoma and carcinoma metastasis with occult primary site. A proper workup can determine the diagnosis and guide the appropriate treatment.

Outcome After Treatment of Patients with Mammographically Occult, Magnetic Resonance Imaging—Detected Breast Cancer Presenting with Axillary Lymphadenopathy

2004 ◽  
Vol 5 (1) ◽  
pp. 72-77 ◽  
Author(s):  
Changhu Chen ◽  
Susan G. Orel ◽  
Eleanor Harris ◽  
Mitchell D. Schnall ◽  
Brian J. Czerniecki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Resonance Imaging ◽  
Axillary Lymphadenopathy

scholarly journals Axillary Lymphadenopathy that Suggestive Breast Cancer Recurrence: A Case Report

2012 ◽  
Vol 45 (1) ◽  
pp. 29-31
Author(s):  
Fatma Buğdaycı Başal ◽  
Umut Demirci ◽  
Mehmet Doğan ◽  
Lütfi Doğan ◽  
Ayşe Demirci ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Cancer Recurrence ◽  
Breast Cancer Recurrence ◽  
Axillary Lymphadenopathy

Rapid and prolonged palliation of symptoms with improved quality of life (QOL) with endocrine therapy (anastrazole) in metastatic breast cancer (MBC)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10767-10767
Author(s):  
J. Samuel ◽  
D. Osafo
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Lymph Node ◽  
Pleural Effusion ◽  
Endocrine Therapy ◽  
Primary Breast Cancer ◽  
Metastatic Breast ◽  
Electrolyte Imbalance ◽  
Axillary Lymphadenopathy ◽  
Post Menopausal

10767 Background: Efficacy of anastrazole in receptor positive post-menopausal MBC; rapid palliation of symptoms with improved QOL. Methods: Case Report: A 62 year old woman diagnosed with right breast cancer in 1995, stage IIB, underwent surgery, adjuvant chemotherapy, and tamoxifen for 5 years. In February 2004, a left supraclavicular lymph node (1 cm) was felt. Chest x-ray (CXR) showed blunting of right cardiophrenic angle. CT scan of the neck showed multiple left cervical lymph nodes. In April 2004, her condition deteriorated rapidly needing hospitalization. She developed 15 pound weight loss, anemia, anorexia, shortness of breath, dyspnea on exertion, dry cough, and chest pain. CXR showed large right pleural effusion needing multiple thoracentesis. Hemorrhagic exudative effusion was seen with negative cytology and cultures. She also developed multiple palpable left cervical and left axillary lymphadenopathy. Breast exam was normal. Mammogram was not diagnostic but ultrasound of breast showed a 2.5cm left breast mass, axillary lymphadenopathy and additional lesions in the breast. Left cervical lymph node biopsy showed metastatic adenocarcinoma favoring primary breast cancer. A diagnosis of 2nd primary breast cancer with metastasis was made. Within 1 week of palliative capecitabine, she was readmitted with significant mucositis, diarrhea, dehydration, dysphagia, electrolyte imbalance, and reaccumulation of right pleural effusion. She lost 35 lbs. in 4 months. She was aggressively resuscitated and also needed thoracocentesis. Markers from prior biopsy showed Estrogen receptor 20%, Progesterone receptor <5%, and HER 2 (Herceptest) 3+. Palliative hormonal therapy with anastrazole was started in July 2004. Results: Within 4 weeks, she improved significantly with disappearance of lymphadenopathy and resolution of effusion. Performance status improved to ECOG 0. She is continuing anastrazole, 17 months since the diagnosis of debilitating metastatic breast cancer. Conclusions: Anastrazole is approved for the treatment of hormone receptor positive post-menopausal MBC. We describe the efficacy of endocrine therapy (anastrazole) leading to rapid and meaningful palliation of symptoms with improved QOL. No significant financial relationships to disclose.

scholarly journals Updates in COVID-19 Related Lymphadenopathy - Frequent Deep Axillary Location and Possible Contralateral Involvement

2021 ◽  
Vol 6 (10) ◽  
pp. 725-730
Author(s):  
Pintican Roxana ◽  
Duma Magdalena ◽  
Szep Madalina ◽  
Schiau Calin ◽  
Feier Diana ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Emotional Stress ◽  
Side Effect ◽  
Breast Cancer Patients ◽  
Oncology Patients ◽  
Axillary Lymphadenopathy ◽  
Cancer Management ◽  
Breast Cancer Management

Ipsilateral axillary lymphadenopathy related to COVID-19 vaccine was reported as a side effect and started to raise diagnostic dilemmas especially in oncology patients. Breast cancer patients are particularly prone to this benign pitfall that may result in unfortunate management changing or unnecessary biopsy, both causing additional emotional stress for the patients. We present three cases with axillary lymphadenopathy and one with axillary and bilateral supraclavicular lymphadenopathy, and focus on what haven’t been reported yet: the deep and more superior location for the axillary lymphadenopathy and the possibility of contralateral lymphadenopathy secondary to COVID-19 vaccine. Their implication in breast cancer management will also be briefly discussed.

Sign in / Sign up

Export Citation Format

Share Document